HRS-2129
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Acute Pain
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07377721 NCT07377721 · Diabetic Peripheral Neuropathic Pain Registry: NCT07377721 | 1 | Compare the change from baseline in Average Daily Pain Score (ADPS) between HRS-2129 and placebo at Week 4. (Baseline and Week 4.) 2026-09 | In progress: primary completion was expected 1 Sept 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Acute Pain: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-2129: this drug | Stage not on record | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Bupivacaine Liposome (Exparel) | Approved | Small molecule | Amide Local Anesthetic | not yet graded | No reviewed efficacy summary in this indication | |
| Suzetrigine (Journavx) | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | Reliable signal | NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5) NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3) |
Upcoming events
No upcoming readouts on record for this asset.